Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM.

Lancet Oncol. 2019 Oct;20(10):1432-1443. doi: 10.1016/S1470-2045(19)30408-5. Epub 2019 Sep 9.

PMID:
31515154
2.

PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-0317. [Epub ahead of print]

PMID:
31439587
3.

Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans.

Xu J, Chang WS, Tsai CW, Bau DT, Davis JW, Thompson TC, Logothetis CJ, Gu J.

Carcinogenesis. 2019 Aug 13. pii: bgz139. doi: 10.1093/carcin/bgz139. [Epub ahead of print]

PMID:
31408512
4.

The role of lineage plasticity in prostate cancer therapy resistance.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.

Clin Cancer Res. 2019 Jul 30. pii: clincanres.1423.2019. doi: 10.1158/1078-0432.CCR-19-1423. [Epub ahead of print]

PMID:
31363002
5.

Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.

Huang L, Brunell D, Stephan C, Mancuso J, Yu X, He B, Thompson TC, Zinner R, Kim J, Davies P, Wong STC.

Bioinformatics. 2019 Oct 1;35(19):3709-3717. doi: 10.1093/bioinformatics/btz109.

6.

N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches.

Thompson TC, Liu B, Li L.

Oncoscience. 2018 Aug 22;5(11-12):273-275. doi: 10.18632/oncoscience.462. eCollection 2018 Nov. No abstract available.

7.

Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.

Wang Q, Gregg JR, Gu J, Ye Y, Chang DW, Davis JW, Thompson TC, Kim J, Logothetis CJ, Wu X.

Oncoimmunology. 2018 Oct 29;8(1):e1483303. doi: 10.1080/2162402X.2018.1483303. eCollection 2019.

PMID:
30546938
8.

Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

Lowenstein LM, Basourakos SP, Williams MD, Troncoso P, Gregg JR, Thompson TC, Kim J.

Nat Rev Clin Oncol. 2019 Mar;16(3):168-184. doi: 10.1038/s41571-018-0116-x. Review.

PMID:
30413793
9.

ER stress in prostate cancer: A therapeutically exploitable vulnerability?

Logothetis C, Aparicio A, Thompson TC.

Sci Transl Med. 2018 May 2;10(439). pii: eaat3975. doi: 10.1126/scitranslmed.aat3975. Review.

PMID:
29720450
10.

Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.

Liu Y, Tan X, Liu W, Chen X, Hou X, Shen D, Ding Y, Yin J, Wang L, Zhang H, Yu Y, Hou J, Thompson TC, Cao G.

Chin J Cancer. 2018 Jan 22;37(1):2. doi: 10.1186/s40880-018-0267-2.

11.

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.

Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC.

Int J Cancer. 2018 May 15;142(10):2163-2174. doi: 10.1002/ijc.31237. Epub 2018 Jan 30.

12.

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.

Thompson TC, Li L, Broom BM.

Oncotarget. 2017 Oct 25;8(55):93315-93316. doi: 10.18632/oncotarget.22074. eCollection 2017 Nov 7. No abstract available.

13.

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC.

Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14.

14.

Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer.

Thompson TC, Li L.

Mol Cell Oncol. 2017 May 3;4(4):e1321167. doi: 10.1080/23723556.2017.1321167. eCollection 2017.

15.

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J.

BJU Int. 2018 Jan;121(1):69-76. doi: 10.1111/bju.13963. Epub 2017 Aug 16.

16.

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.

Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

17.

Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer.

Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X.

Oncol Lett. 2017 Mar;13(3):1949-1957. doi: 10.3892/ol.2017.5616. Epub 2017 Jan 18.

18.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

19.

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC.

Curr Med Chem. 2017;24(15):1586-1606. doi: 10.2174/0929867323666161214114948. Review.

20.

Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.

Shu X, Ye Y, Gu J, He Y, Davis JW, Thompson TC, Logothetis CJ, Kim J, Wu X.

Carcinogenesis. 2016 Oct;37(10):965-971. doi: 10.1093/carcin/bgw082. Epub 2016 Aug 11.

21.

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.

Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC.

Oncotarget. 2016 Jul 19;7(29):46321-46334. doi: 10.18632/oncotarget.10113.

22.

A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression.

Liu Y, Han X, Yu Y, Ding Y, Ni C, Liu W, Hou X, Li Z, Hou J, Shen D, Yin J, Zhang H, Thompson TC, Tan X, Cao G.

Sci Rep. 2016 May 26;6:26689. doi: 10.1038/srep26689.

23.

Regulation of Phagolysosomal Digestion by Caveolin-1 of the Retinal Pigment Epithelium Is Essential for Vision.

Sethna S, Chamakkala T, Gu X, Thompson TC, Cao G, Elliott MH, Finnemann SC.

J Biol Chem. 2016 Mar 18;291(12):6494-506. doi: 10.1074/jbc.M115.687004. Epub 2016 Jan 26.

24.

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ.

Clin Cancer Res. 2016 Mar 15;22(6):1520-30. doi: 10.1158/1078-0432.CCR-15-1259. Epub 2015 Nov 6.

25.

Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer.

Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X.

Oncotarget. 2015 Dec 8;6(39):41988-96. doi: 10.18632/oncotarget.5889.

26.

Retinal Caveolin-1 Modulates Neuroprotective Signaling.

Reagan A, Gu X, Hauck SM, Ash JD, Cao G, Thompson TC, Elliott MH.

Adv Exp Med Biol. 2016;854:411-8. doi: 10.1007/978-3-319-17121-0_54.

PMID:
26427439
27.

Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.

Yin J, Wang J, Pu R, Xin H, Li Z, Han X, Ding Y, Du Y, Liu W, Deng Y, Ji X, Wu M, Yu M, Zhang H, Wang H, Thompson TC, Ni W, Cao G.

Cancer Prev Res (Phila). 2015 Oct;8(10):978-88. doi: 10.1158/1940-6207.CAPR-15-0160. Epub 2015 Aug 19.

28.

Enhanced central memory cluster of differentiation 8+ and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy.

Kubo M, Satoh T, Tabata KI, Tsumura H, Iwamura M, Baba S, Thompson TC, Obata F.

Mol Clin Oncol. 2015 May;3(3):515-521. Epub 2015 Feb 26.

29.

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.

Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, Thompson TC.

Mol Cancer. 2015 Jun 19;14:122. doi: 10.1186/s12943-015-0395-0.

30.

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.

Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Review.

31.

New targets for resistant prostate cancer.

Thompson TC, Li L.

Oncotarget. 2014 Oct 15;5(19):8816-7. No abstract available.

32.

Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance.

Karanika S, Karantanos T, Yin J, Li L, Thompson TC.

Asian J Urol. 2014 Oct;1(1):30-39. doi: 10.1016/j.ajur.2015.04.004. Epub 2015 Apr 16. Review.

33.

Environmental and psycho-social factors related to prostate cancer risk in the Chinese population: a case-control study.

Li ML, Lin J, Hou JG, Xu L, Cui XG, Xu XX, Yu YW, Han X, Wang GM, Guo JM, Xu DF, Thompson TC, Cao GW, Zhang HW.

Biomed Environ Sci. 2014 Sep;27(9):707-17. doi: 10.3967/bes2014.089.

34.

DNA damage response and prostate cancer: defects, regulation and therapeutic implications.

Karanika S, Karantanos T, Li L, Corn PG, Thompson TC.

Oncogene. 2015 May 28;34(22):2815-22. doi: 10.1038/onc.2014.238. Epub 2014 Aug 18. Review.

35.

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC.

Sci Signal. 2014 May 20;7(326):ra47. doi: 10.1126/scisignal.2005070.

36.

Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer.

Karantanos T, Tanimoto R, Edamura K, Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S, Thompson TC.

Int J Cancer. 2014 Apr 15;134(8):2003-13. doi: 10.1002/ijc.28529. Epub 2013 Nov 1.

37.

Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression.

Tan X, Wang Y, Han Y, Chang W, Su T, Hou J, Xu D, Yu Y, Ma W, Thompson TC, Cao G.

Br J Cancer. 2013 Dec 10;109(12):3105-15. doi: 10.1038/bjc.2013.669. Epub 2013 Oct 24.

38.

GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer.

Karantanos T, Thompson TC.

Cancer Cell. 2013 Jul 8;24(1):11-3. doi: 10.1016/j.ccr.2013.06.007. Erratum in: Cancer Cell. 2013 Aug 12;24(2):272.

39.

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Karantanos T, Corn PG, Thompson TC.

Oncogene. 2013 Dec 5;32(49):5501-11. doi: 10.1038/onc.2013.206. Epub 2013 Jun 10. Review.

40.

Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.

Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC, Lisanti MP, Freeman MR, Vizio DD.

J Pathol. 2013 Sep;231(1):77-87. doi: 10.1002/path.4217. Epub 2013 Jul 8.

41.

Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models.

Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, Naruishi K, Yang G, Goltsov A, Wang J, Vlachaki MT, Teh BS, Brian Butler E, Thompson TC.

Urol Oncol. 2014 Feb;32(2):92-100. doi: 10.1016/j.urolonc.2012.10.007. Epub 2013 Feb 20.

42.

Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.

Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC.

Mol Oncol. 2013 Jun;7(3):484-96. doi: 10.1016/j.molonc.2012.12.005. Epub 2012 Dec 31.

43.

Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer.

Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, Chang W, Thompson TC.

Cancer Res. 2013 Mar 15;73(6):1900-11. doi: 10.1158/0008-5472.CAN-12-3040. Epub 2013 Jan 9.

44.

Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models.

Tahir SA, Kurosaka S, Tanimoto R, Goltsov AA, Park S, Thompson TC.

Cancer Biol Ther. 2013 Feb;14(2):117-26. doi: 10.4161/cbt.22633. Epub 2012 Oct 31.

45.

Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.

Hu J, Lu JY, Wong AM, Hynan LS, Birnbaum SG, Yilmaz DS, Streit BM, Lenartowicz EM, Thompson TC, Cooper JD, Hofmann SL.

Mol Genet Metab. 2012 Sep;107(1-2):213-21. doi: 10.1016/j.ymgme.2012.05.009. Epub 2012 May 22.

46.

Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics.

Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE, Liu JS.

Hybridoma (Larchmt). 2012 Apr;31(2):77-86. doi: 10.1089/hyb.2011.0100.

47.

Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.

Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC.

Mol Cancer Res. 2012 Feb;10(2):218-29. doi: 10.1158/1541-7786.MCR-11-0451. Epub 2011 Dec 5.

48.

GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.

Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC.

Cancer Res. 2011 Dec 15;71(24):7694-704. doi: 10.1158/0008-5472.CAN-11-1714. Epub 2011 Oct 24.

49.

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.

Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D.

Clin Cancer Res. 2011 Nov 15;17(22):7174-82. doi: 10.1158/1078-0432.CCR-11-1899. Epub 2011 Sep 20.

50.

Castration-induced changes in mouse epididymal white adipose tissue.

Floryk D, Kurosaka S, Tanimoto R, Yang G, Goltsov A, Park S, Thompson TC.

Mol Cell Endocrinol. 2011 Oct 15;345(1-2):58-67. doi: 10.1016/j.mce.2011.07.011. Epub 2011 Jul 12.

Supplemental Content

Loading ...
Support Center